H.C. Wainwright analyst Joseph Pantginis lowered the firm’s price target on CalciMedica (CALC) to $16 from $20 and keeps a Buy rating on the shares. The firm believes the Phase 2b CARPO data “represent a significant step forward” in the clinical advancement of Auxora. It cites dilution from the equity raise for the target cut.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter